Phase 1/2 trial of ALN-SOD opens recruiting sites in Germany, Poland
Original source
Phase 1/2 trial of ALN-SOD opens recruiting sites in Sweden (opens in a new tab)1 further copy of this report was also considered.
Trial at a glance
- Status
- Recruiting
- Phase
- Phase 1/2
- Intervention
- ALN-SOD (drug)
- Enrolment
- 54 participants (estimated)
- Sites
- Australia, Belgium, Canada, Germany, Japan, South Korea, Poland, Sweden, Taiwan
- Sponsor
- Regeneron Pharmaceuticals
- Registration
- NCT06351592
Compass reports what the trial registry states. A trial being registered, recruiting or completed is not evidence that a treatment works.
This Phase 1/2 interventional study is testing ALN-SOD and a diluent in adults with SOD1-associated ALS. The registry now lists sites in Germany and Poland, alongside sites in Australia, Belgium, Canada, Japan, South Korea, Sweden and Taiwan. Recruitment is listed as ongoing, with 54 participants estimated.
Why this matters
The addition of Germany and Poland means the study now has listed sites in those countries. The registry does not provide site-specific recruitment status, so this update does not show whether participants can currently join at either location.
Trial updates
New location — 22 July 2026
- 22 June 2026New location
Compass began tracking this trial’s registry record on the date of its first update above. Changes before then are not listed.